Literature DB >> 21584846

Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression.

Marco Atteritano1, Antonino Lasco, Susanna Mazzaferro, Ida Macrì, Antonino Catalano, Antonino Santangelo, Gianluca Bagnato, Gianfilippo Bagnato, Nicola Frisina.   

Abstract

Low bone mineral density, which increases the risk of stress fragility fractures, is a frequent, often persistent finding in patients with major depressive disorder (MDD). The clinical association between major depressive disorder and osteopenia is still unclear, although several factors are associated with a loss of bone mass. The aim of our study, therefore, was to evaluate bone mineral density and bone metabolism in patients with MDD. Bone mineral density was evaluated in fifty postmenopausal women with MDD, and in 50 matched postmenopausal control women by dual-energy X-ray absorptiometry of the lumbar spine and femur, and by ultrasonography of the calcaneus and phalanges. Serum levels of 25-hydroxivitamin D, parathyroid hormone, Osteoprotegerin/Receptor Activator for Nuclear Factor κB Ligand ratio, bone turnover markers, serum and urinary cortisol were examined. Bone mineral density of the lumbar spine (BMD: 0.72 ± 0.06 vs. 0.82 ± 0.09 g/cm(2), p < 0.001), femoral neck (BMD: 0.58 ± 0.04 vs. 0.71 ± 0.07 g/cm(2), p < 0.001) and total femur (BMD 0.66 ± 0.09 vs. 0.54 ± 0.06 g/cm(2), p < 0.001); and ultrasound parameters at calcaneus (SI: 81.30 ± 6.10 vs. 93.80 ± 7.10, p < 0.001) and phalanges (AD-SOS: 1915.00 ± 37.70 vs. 2020.88 ± 39.46, p < 0.001; BTT : 1.30 ± 0.8 vs. 1.45 ± 0.9, p < 0.001) are significantly lower in patients with MDD compared with controls. Moreover bone turnover markers, parathyroid hormone levels and Receptor Activator for Nuclear Factor κB Ligand are significantly higher in MDD patients compared with controls, while serum levels of 25-hydroxivitamin D and osteoprotegerin are significantly lower. There are no differences in urinary excretion and serum cortisol between groups. Postmenopausal women with depressive disorder have an elevated risk for osteoporosis. Our data suggest that a high level of parathyroid hormone may play a role in the pathogenetic process underlying osteopenia in these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21584846     DOI: 10.1007/s11739-011-0628-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  33 in total

Review 1.  Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases.

Authors:  L C Hofbauer; A E Heufelder
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

2.  A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.

Authors:  P Lips; T Duong; A Oleksik; D Black; S Cummings; D Cox; T Nickelsen
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study.

Authors:  Felice N Jacka; Julie A Pasco; Margaret J Henry; Mark A Kotowicz; Seetal Dodd; Geoff C Nicholson; Michael Berk
Journal:  Menopause       Date:  2005 Jan-Feb       Impact factor: 2.953

5.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

Authors:  S K Lee; J A Lorenzo
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

Review 6.  Depression: a major, unrecognized risk factor for osteoporosis?

Authors:  G Cizza; P Ravn; G P Chrousos; P W Gold
Journal:  Trends Endocrinol Metab       Date:  2001-07       Impact factor: 12.015

7.  Bone mineral density in women with depression.

Authors:  D Michelson; C Stratakis; L Hill; J Reynolds; E Galliven; G Chrousos; P Gold
Journal:  N Engl J Med       Date:  1996-10-17       Impact factor: 91.245

8.  Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong).

Authors:  Samuel Y S Wong; Edith M C Lau; Henry Lynn; P C Leung; Jean Woo; Steve R Cummings; Eric Orwoll
Journal:  Osteoporos Int       Date:  2004-09-23       Impact factor: 4.507

9.  Low lumbar bone mineral density in patients with major depression.

Authors:  U Schweiger; M Deuschle; A Körner; C H Lammers; J Schmider; U Gotthardt; F Holsboer; I Heuser
Journal:  Am J Psychiatry       Date:  1994-11       Impact factor: 18.112

Review 10.  Depression and low bone mineral density: a meta-analysis of epidemiologic studies.

Authors:  Q Wu; J H Magnus; J Liu; A F Bencaz; J G Hentz
Journal:  Osteoporos Int       Date:  2009-04-03       Impact factor: 4.507

View more
  20 in total

1.  Fractures in users of antidepressants and anxiolytics and sedatives: effects of age and dose.

Authors:  P Vestergaard; D Prieto-Alhambra; M K Javaid; C Cooper
Journal:  Osteoporos Int       Date:  2012-06-06       Impact factor: 4.507

2.  Depression and risk of hip fracture: a systematic review and meta-analysis of cohort studies.

Authors:  T T Shi; M Min; Y Zhang; C Y Sun; M M Liang; Y H Sun
Journal:  Osteoporos Int       Date:  2019-04-11       Impact factor: 4.507

3.  Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.

Authors:  A Catalano; A Gaudio; R M Agostino; N Morabito; F Bellone; A Lasco
Journal:  J Endocrinol Invest       Date:  2019-05-24       Impact factor: 4.256

4.  Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.

Authors:  A Catalano; A Gaudio; N Morabito; G Basile; R M Agostino; A Xourafa; M Atteritano; E Morini; G Natale; A Lasco
Journal:  J Endocrinol Invest       Date:  2017-03-22       Impact factor: 4.256

Review 5.  Could use of Selective Serotonin Reuptake Inhibitors During Lactation Cause Persistent Effects on Maternal Bone?

Authors:  Samantha R Weaver; Laura L Hernandez
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-03-30       Impact factor: 2.673

6.  Acute effect of zoledronic acid on the risk of cardiac dysrhythmias.

Authors:  Cristiana Cipriani; Claudia Castro; Mario Curione; Sara Piemonte; Federica Biamonte; Claudio Savoriti; Jessica Pepe; Federica De Lucia; Carolina Clementelli; Luciano Nieddu; Salvatore Minisola
Journal:  Intern Emerg Med       Date:  2014-09-05       Impact factor: 3.397

Review 7.  Pain in Osteoporosis: From Pathophysiology to Therapeutic Approach.

Authors:  Antonino Catalano; Gabriella Martino; Nunziata Morabito; Claudia Scarcella; Agostino Gaudio; Giorgio Basile; Antonino Lasco
Journal:  Drugs Aging       Date:  2017-10       Impact factor: 3.923

8.  Depressive symptoms are associated with lower bone mineral density in young adults with high job strain. The Cardiovascular Risk in Young Finns Study.

Authors:  M Oikonen; M Hintsanen; M Laaksonen; V Mikkilä; M Kähönen; T Lehtimäki; L Pulkki-Råback; J S A Viikari; L Keltikangas-Järvinen; O T Raitakari
Journal:  Int J Behav Med       Date:  2014-06

9.  Dualities of the vitamin D in systemic sclerosis: a systematic literature review.

Authors:  Laiana Schneider; Vanessa Hax; Odirlei Monticielo; Tamires Ferri Macedo; Roberta Kern Menna Barreto; Natália Aydos Marcondes; Rafael Chakr
Journal:  Adv Rheumatol       Date:  2021-06-09

10.  Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis.

Authors:  Antonino Catalano; Federica Bellone; Domenico Santoro; Peter Schwarz; Agostino Gaudio; Giorgio Basile; Maria Carmela Sottile; Sabrina Atena Stoian; Francesco Corica; Nunziata Morabito
Journal:  Nutrients       Date:  2021-05-31       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.